325 related articles for article (PubMed ID: 29920603)
1. The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Spencer E; Norris E; Williams C; Dubinsky MC
Inflamm Bowel Dis; 2019 Jan; 25(1):142-149. PubMed ID: 29920603
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.
Ooi CY; Bohane TD; Lee D; Naidoo D; Day AS
Aliment Pharmacol Ther; 2007 Apr; 25(8):941-7. PubMed ID: 17402998
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Haines ML; Ajlouni Y; Irving PM; Sparrow MP; Rose R; Gearry RB; Gibson PR
Inflamm Bowel Dis; 2011 Jun; 17(6):1301-7. PubMed ID: 20812329
[TBL] [Abstract][Full Text] [Related]
5. Thiopurine metabolite testing in inflammatory bowel disease.
Goldberg R; Moore G; Cunningham G; Schulberg J; Marsh P; Brown S; Connell W; Lust M; Kamm MA; Bell S
J Gastroenterol Hepatol; 2016 Mar; 31(3):553-60. PubMed ID: 26510636
[TBL] [Abstract][Full Text] [Related]
6. Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
Nguyen TV; Vu DH; Nguyen TM; Lachaux A; Boulieu R
Ther Drug Monit; 2013 Apr; 35(2):251-7. PubMed ID: 23503453
[TBL] [Abstract][Full Text] [Related]
7. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.
Lee MN; Kang B; Choi SY; Kim MJ; Woo SY; Kim JW; Choe YH; Lee SY
Inflamm Bowel Dis; 2015 May; 21(5):1054-62. PubMed ID: 25851563
[TBL] [Abstract][Full Text] [Related]
8. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic.
Smith M; Blaker P; Patel C; Marinaki A; Arenas M; Escuredo E; Anderson S; Irving P; Sanderson J
Int J Clin Pract; 2013 Feb; 67(2):161-9. PubMed ID: 23253089
[TBL] [Abstract][Full Text] [Related]
9. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?
Heerasing NM; Ng JF; Dowling D
Intern Med J; 2016 Apr; 46(4):465-9. PubMed ID: 26425841
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche J; Desager JP; Horsmans Y; Louis E
Scand J Gastroenterol; 2001 Jan; 36(1):71-6. PubMed ID: 11218242
[TBL] [Abstract][Full Text] [Related]
11. Optimizing immunomodulator therapy for inflammatory bowel disease.
Dubinsky MC
Curr Gastroenterol Rep; 2003 Dec; 5(6):506-11. PubMed ID: 14602061
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
Nguyen TV; Nguyen TM; Lachaux A; Boulieu R
J Clin Pharmacol; 2013 Sep; 53(9):900-8. PubMed ID: 23856979
[TBL] [Abstract][Full Text] [Related]
13. Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine.
Munnig-Schmidt E; Zhang M; Mulder CJ; Barclay ML
Inflamm Bowel Dis; 2018 Mar; 24(4):892-896. PubMed ID: 29522107
[TBL] [Abstract][Full Text] [Related]
14. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
[TBL] [Abstract][Full Text] [Related]
15. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
18. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
19. The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios.
Selinger CP; Ochieng AO; George V; Leong RW
Inflamm Bowel Dis; 2019 Apr; 25(5):919-924. PubMed ID: 30265299
[TBL] [Abstract][Full Text] [Related]
20. Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
Luber RP; Dawson L; Munari S; Kariyawasam VC; Martin C; Gibson PR; Sparrow MP; Ward MG
J Gastroenterol Hepatol; 2021 Apr; 36(4):990-998. PubMed ID: 32881046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
